A Phase 4 interventional study of Dronedarone and Placebo (for Dronedarone) in Atrial Fibrillation, sponsored by Sanofi. Terminated at 57 sites in 2 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2013-02-12.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.
Among the 26 studies testing dronedarone in Atrial Fibrillation, this one is the 20th largest by enrollment, is one of 9 that started in 2010, is one of 11 in phase 4, and was the 13th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:
Shanghai East Hospital · Sites in China
Ages 18–80
Inha University Hospital · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 8 · Phase 4 11
First in 2001; this study’s year is marked. 9 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is below the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.
Median enrollment 164 across the 26 interventional studies. Of the 20 that completed or were terminated, 8 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 26 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
23 studies in Atrial Fibrillation by Sanofi: none open now, none under way, none of them phase 3. Of 23 finished, 7 (30%) have results posted.
Among the 23 studies in Atrial Fibrillation by Sanofi, this one is the 20th largest by enrollment of the 20 interventional ones that give a count, is one of 7 that started in 2010, is one of 6 in phase 4, and was the 20th registered.
Sanofi’s Atrial Fibrillation studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing dronedarone in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 23 in Atrial Fibrillation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary Objectives:
The planned total study period per participant was 12 months and 3 weeks broken down as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Need for concomitant medication that is prohibited in this trial, and would preclude the use of the study drug during the planned study period including the following:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dronedarone 400 mg twice a day
Drug: Dronedarone
Placebo (for Dronedarone) twice a day
Drug: Placebo (for Dronedarone)
Film-coated tablet Oral administration under fed conditions (during breakfast and dinner)
Also known as: Multaq®, SR33589
film-coated tablet strictly identical in appearance Oral administration under fed conditions (during breakfast and dinner)
Change From Baseline in Left Atrial Volume Index (LAVi)
Left Atrial Volume index (LAVi) was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last study drug intake and data were included in the analysis.
Time frame: baseline (before randomization) and post-baseline (after 3-12 months of treatment)
Changes From Baseline in Left Atrial Function
left atrial (LA) function was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last study drug intake and data were included in the analysis.
Time frame: baseline (before randomization) and post-baseline (after 3-12 months of treatment)
Changes From Baseline in Left Atrial Dimension
Maximal left atrial diameter in the anteroposterior dimension was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last drug intake and data were included in the analysis.
Time frame: baseline (before randomization) and post-baseline (after 3-12 months of treatment)
Changes From Baseline in Left Ventricular Ejection Fraction (LVEF)
Left Ventricular Ejection Fraction (LVEF) was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last drug intake and data were included in the analysis.
Time frame: baseline (before randomization) and post-baseline (after 3-12 months of treatment)
Changes From Baseline in Left Ventricular Function
left ventricular (LV) function was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last study drug intake and data were included in the analysis.
Time frame: baseline (before randomization) and post-baseline (after 3-12 months of treatment)
Recruitment initiated in September 2010 was discontinued in September, 2011 due to significantly lower than planned enrollment with no feasibility to complete the trial within reasonable, meaningful timelines. At that time 57 sites in US and Canada had screened at least one patient.
| Milestone | Placebo | Dronedarone |
|---|---|---|
| Started | 41 | 35 |
| Treated | 41 | 35 |
| Evaluable for efficacy | 33 | 26 |
| Completed | 4 | 3 |
| Not completed | 37 | 32 |
| Withdrew: Adverse event | 4 | 7 |
| Withdrew: Study closure | 29 | 23 |
| Withdrew: Other than above | 4 | 2 |
Left Atrial Volume index (LAVi) was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last study drug intake and data were included in the analysis.
| mililiters/m2 | Placebo | Dronedarone |
|---|---|---|
| Baseline (n =33, 26) | 37.555 ± 5.899 | 37.715 ± 6.597 |
| Post-baseline (n =32, 26) | 29.191 ± 5.994 | 30.823 ± 5.364 |
| Change from baseline (n =32, 26) | -8.438 ± 4.743 | -6.892 ± 5.759 |
left atrial (LA) function was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last study drug intake and data were included in the analysis.
| mililiters | Placebo | Dronedarone |
|---|---|---|
| LA passive emptying volume (n = 19, 19) | -10.783 ± 7.798 | -4.566 ± 9.094 |
| LA conduit volume (n =29, 25) | -1.366 ± 5.652 | -0.764 ± 5.759 |
| LA active emptying volume (n = 19, 19) | -0.052 ± 4.707 | 1.198 ± 5.695 |
| LA passive emptying fraction (n = 19, 19) | -0.074 ± 0.074 | -0.019 ± 0.117 |
| LA active emptying fraction (n = 19, 19) | 0.057 ± 0.104 | 0.067 ± 0.105 |
Maximal left atrial diameter in the anteroposterior dimension was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last drug intake and data were included in the analysis.
| centimeters | Placebo | Dronedarone |
|---|---|---|
| Changes From Baseline in Left Atrial Dimension | -0.124 ± 0.188 | -0.166 ± 0.161 |
Left Ventricular Ejection Fraction (LVEF) was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last drug intake and data were included in the analysis.
| percentage of blood pumped out | Placebo | Dronedarone |
|---|---|---|
| Changes From Baseline in Left Ventricular Ejection Fraction (LVEF) | 0.948 ± 3.333 | 1.147 ± 3.997 |
left ventricular (LV) function was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last study drug intake and data were included in the analysis.
| centimeters/second | Placebo | Dronedarone |
|---|---|---|
| Peak early diastolic transmitral flow velocity (E) | 5.165 ± 15.440 | -10.497 ± 27.890 |
| Mitral annular velocity (E') | 0.847 ± 2.002 | -0.119 ± 1.845 |
| Peak late diastolic transmitral flow velocity (A) | 0.076 ± 11.674 | 4.319 ± 14.275 |
| E/E' ratio | -0.787 ± 3.346 | -1.443 ± 4.288 |
Collected over All Adverse Events (AE) were collected regardless of seriousness or relationship to the drug in the period spanning from signature of the Informed Consent Form up to the last visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/41 (2.4%) | 5/41 (12.2%) |
| Dronedarone | — | 5/35 (14.3%) | 14/35 (40%) |
| Event | Placebo | Dronedarone |
|---|---|---|
| Cardiac failure congestiveCardiac disorders | 0/41 | 1/35 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/41 | 1/35 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/41 | 1/35 |
| Pancreatic cystGastrointestinal disorders | 0/41 | 1/35 |
| Gouty arthritisMusculoskeletal and connective tissue disorders | 0/41 | 1/35 |
| Renal failure acuteRenal and urinary disorders | 0/41 | 1/35 |
| AstheniaGeneral disorders | 0/41 | 1/35 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/41 | 1/35 |
| Angina pectorisCardiac disorders | 1/41 | 0/35 |
| Atrial fibrillationCardiac disorders | 1/41 | 0/35 |
| Event | Placebo | Dronedarone |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/41 | 4/35 |
| FatigueGeneral disorders | 1/41 | 4/35 |
| InsomniaPsychiatric disorders | 0/41 | 3/35 |
| DizzinessNervous system disorders | 0/41 | 3/35 |
| NauseaGastrointestinal disorders | 0/41 | 3/35 |
| HypertensionVascular disorders | 3/41 | 0/35 |
| PneumoniaInfections and infestations | 0/41 | 2/35 |
| SinusitisInfections and infestations | 0/41 | 2/35 |
| DepressionPsychiatric disorders | 0/41 | 2/35 |
| ConstipationGastrointestinal disorders | 0/41 | 2/35 |
| Age Continuous(years) | Placebo | Dronedarone | Total |
|---|---|---|---|
| Mean | 70.3 ± 8.2 | 74.1 ± 9.7 | 72.0 ± 9.1 |
| Sex: Female, Male(Participants) | Placebo | Dronedarone | Total |
|---|---|---|---|
| Female | 15 | 13 | 28 |
| Male | 26 | 22 | 48 |
The record gives a start of Sep 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dronedarone